MK-0616 is a peptide commercialized by Merck, with a leading Phase III program in Heterozygous familial hypercholesterolemia (heFH). According to Globaldata, it is involved in 11 clinical trials, of which 3 were completed, 7 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of MK-0616’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for MK-0616 is expected to reach an annual total of $1.08 bn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
MK-0616 is under development for the treatment of atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia such as heterozygous familial hypercholesterolemia (heFH). It is administered through oral route. The drug candidate acts by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
The company reported revenues of (US Dollars) US$59,283 million for the fiscal year ended December 2022 (FY2022), an increase of 21.7% over FY2021. In FY2022, the company’s operating margin was 30.3%, compared to an operating margin of 25.7% in FY2021. In FY2022, the company recorded a net margin of 24.5%, compared to a net margin of 26.8% in FY2021. The company reported revenues of US$15,035 million for the second quarter ended June 2023, an increase of 3.8% over the previous quarter.
For a complete picture of MK-0616’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.